Inventiva (IVA) Total Liabilities (2018 - 2025)
Inventiva (IVA) posted quarterly Total Liabilities of $323.6 million for Q4 2025, up 34.24% year-over-year from $241.1 million in Q4 2024, and up 52.19% quarter-over-quarter from $212.7 million in Q2 2025.
Analysis
Inventiva (IVA) Total Liabilities (2018 - 2025) Analysis & Trends
Inventiva's Total Liabilities history runs 8 years deep, the most recent figure standing at $323.6 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 34.24% year-over-year to $323.6 million; the TTM figure through Dec 2025 stood at $323.6 million (up 34.24% YoY), while the FY2025 annual figure was $323.6 million, up 34.24% from the prior year.
- Total Liabilities for Q4 2025 stood at $323.6 million, up from $212.7 million in the prior quarter.
- The five-year high for Total Liabilities was $323.6 million in Q4 2025, with the low at $115662.5 in Q2 2022.
- The 5-year median for Total Liabilities is $93.2 million (2023), against an average of $117.0 million.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities tumbled 99.92% in 2022, then jumped 66573.73% in 2023.
- Inventiva's Total Liabilities stood at $37.9 million in 2021, then soared by 89.92% to $72.0 million in 2022, then surged by 51.91% to $109.3 million in 2023, then soared by 120.56% to $241.1 million in 2024, then soared by 34.24% to $323.6 million in 2025.
- Business Quant data shows IVA's Total Liabilities at $323.6 million in Q4 2025, $212.7 million in Q2 2025, and $241.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | 323.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 323.64 Mn |
| Jun 30, 2025 | 212.65 Mn |
| Dec 31, 2024 | 241.09 Mn |
| Jun 30, 2024 | 118.46 Mn |
| Dec 31, 2023 | 109.31 Mn |
| Jun 30, 2023 | 78.57 Mn |
| Dec 31, 2022 | 71.96 Mn |
| Jun 30, 2022 | 35.00 Mn |
| Dec 31, 2021 | 37.89 Mn |
| Jun 30, 2021 | 26.14 Mn |
| Mar 31, 2021 | 27.04 Mn |
| Dec 31, 2020 | 24.06 Mn |
| Jun 30, 2020 | 22.62 Mn |
| Dec 31, 2019 | 10.62 Mn |
| Dec 31, 2018 | 20.79 Mn |